Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2013, Vol. 11 ›› Issue (4): 285-290.doi: 10.3736/jintegrmed2013035

• Study Protocol • Previous Articles     Next Articles

Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson’s disease: Study protocol of a multicenter, open-label, randomized active-controlled trial

Jie Zhanga,b, Yun-zhi Mab(), Xiao-ming Shenb   

  1. a. Department of Cerebropathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
    b. Department of Cerebropathy, the First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, Henan Province, China
  • Received:2013-03-02 Accepted:2013-04-02 Online:2013-07-10 Published:2013-07-15

Background

Parkinson’s disease (PD) is a complicated disease, commonly diagnosed among the elderly, which leads to degeneration of the central nervous system. It presently lacks an effective therapy for its complex pathogenesis. Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients. Traditional Chinese medicine (TCM) has long been used to improve the treatment of PD by alleviating the toxic and adverse effects of Western drug-based intervention. Therefore, the aim of this study is to evaluate the efficacy and safety of Xifeng Dingchan Pill (XFDCP), a compound traditional Chinese herbal medicine, taken in conjunction with Western medicine in the treatment of PD patients at different stages in the progression of the disease.


Methods and design

This is a multicenter, randomized controlled trial. In total, 320 patients with early- (n = 160) and middle-stage PD (n = 160) will be enrolled and divided evenly into control and trial groups. Of the 160 patients with early-stage PD, the trial group (n = 80) will be given XFDCP, and the control group (n = 80) will be given Madopar. Of the 160 patients with middle-stage PD, the trial group (n = 80) will be given XFDCP combined with Madopar and Piribedil, and the control group (n = 80) will be given Madopar and Piribedil. The Unified Parkinson’s Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar’s dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period.


Discussion

It is hypothesized that XFDCP, combined with Madopar and Piribedil, will have beneficial effects on patients with PD. The results of this study will provide evidence for developing a comprehensive therapy regimen, which can delay the progress of the disease and improve the quality of life for PD patients in different stages.


Trial Registration

This trial has been registered in the Chinese Clinical Trial Registry with the identifer ChiCTR-TRC-12002150.

Key words: Parkinson disease, Levodopa, Drugs, Chinese herbal, Drug toxicity, Randomized controlled trial, Clinical protocols

"

Figure 1

Procedure of this studyUPDRS: Unified Parkinson’s Disease Rating Scale; TCM: traditional Chinese medicine."

[1] Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, Zhou B, Geng ZP, Wu JX, Wen HB, Zhao H, Zahner GE . Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai[J]. Lancet, 2005,365(9459):595-597
doi: 10.1016/S0140-6736(05)70801-1
[2] Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030[J]. Neurology, 2007,68(5):384-386
doi: 10.1212/01.wnl.0000247740.47667.03
[3] Wang Y, Yin S, Liu WG, Bian Y, Wang BM, Ye M, Lin XJ, Zhang L . Investigation on economic burden of disease and its related influence factors in patients with Parkinson disease[J]. Lin Chuang Shen Jing Bing Xue Za Zhi, 2011,24(6):427-430
[4] Bai QL, Feng Z . Effect of nourishing liver-kidney and extinguishing wind on Parkinson’s disease of liver-kidney deficiency symptom[J]. Liaoning Zhong Yi Za Zhi, 2010,37(5):846-849
[5] Ma YZ, Liu J, Wang BQ, Li SF, Fu AM, Fang J, Lu SL, Lü FZ, Shen XM, Jia K, Zuo QX, Zhuang ZJ, Zhang M, Zhou XQ , Liu SS. Study on the effects of Xifeng Dingchan Pill in improving the efficiency and alleviating the toxicity symptoms of Madopar in patients with Parkinson’s disease. National Achievement of Science and Technology. ( 2004[ 2012-12-14]. .
[6] Bai QL, Ma YZ . Effect of Xifeng Dingchan Pill on syndrome of liver and kidney deficiency of Parkinson’s disease: a report of 30 cases[J]. Zhong Yi Za Zhi, 2010,51(2):125-127, 131
[7] Ma YZ, Li SF, Shen XM, Jia K . Research on efficiency of traditional Chinese and Western medicine in treating 30 patients with Parkinson disease[J]. Xin Zhong Yi, 2005,37(10):55-56
[8] Ma L . A study on effects of Xifeng Dingchan Pill in treating 40 patients with Parkinson’s disease[J]. Zhong Yi Yan Jiu, 2008,21(3):39-42
[9] Chen CH, Ma YZ, Ma L, Wang JF . Study on the effects of Xifeng Dingchan Pill on the Madopar dosage on Parkinson’s disease[J]. Shanxi Zhong Yi, 2007,23(1):35-36
[10] Gelb DJ, Oliver E, Gilman S . Diagnostic criteria for Parkinson disease[J]. Arch Neurol, 1999,56(1):33-39
doi: 10.1001/archneur.56.1.33
[11] Movement Disorder and Parkinson’s Disease Group of Chinese Society of Neurology. Guidelines for the treament of Parkinson’s disease[J]. Zhonghua Shen Jing Ke Za Zhi, 2009,42(5):352-355
[12] China Association of Traditional Chinese Medicine for Senile Encephalopathy. Diagnosis and efficacy evaluation criteria for senile tremor disease of traditional Chinese medicine[J]. Beijing Zhong Yi Xue Yuan Xue Bao, 1992,15(4):39-41
[13] Zheng XY. Clinical guideline of new drugs for traditional Chinese medicine(Draft)[M]. Beijing: China Medical Science Press, 2002,5
[14] Sun ZQ. Medical statistics.3rd ed[M]. Beijing: People’s Medical Publishing House, 2011, 541-543
[15] Bian ZX, Li YP, Moher D, Dagenais S, Liu L, Wu TX, Miao JX, Guan JL, Song L . Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology[J]. J Chin Integr Med, 2006,4(2):120-129
doi: 10.3736/jcim
[16] Palacios N, Gao X, Schwarzschild M, Ascherio A . Declining quality of life in Parkinson disease before and after diagnosis[J]. J Parkins Dis, 2012,2(2):153-160
[17] Gao HM, Hong JS . Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression[J]. Trends Immunol, 2008,29(8):357-365
doi: 10.1016/j.it.2008.05.002
[18] Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F . Levodopa in the treatment of Parkinson’s disease: an old drug still going strong[J]. Clin Interv Aging, 2010,5:229-238
[19] Olanow W, Schapira AH, Rascol O . Continuous dopamine-receptor stimulation in early Pakinson’s disase[J]. Trends Neurosci, 2000,23(10 Suppl):S117-S126
doi: 10.1016/S1471-1931(00)00030-6
[1] Chiung-Hui Huang, Mei-Ling Yeh, Fang-Pey Chen, Daphne Wu. Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: A randomized placebo-controlled trial. Journal of Integrative Medicine, 2022, 20(4): 321-328.
[2] Maryam Azimi, Hanieh Niayesh, Mahboobeh Raeiszadeh, Sedigheh Khodabandeh-shahraki. Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation: A double-blind randomized controlled tria. Journal of Integrative Medicine, 2022, 20(3): 230-236.
[3] Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Ana Elisa Madureira Padula, Livia Mitchiguian Hotta, Amarilysde Toledo Cesar, José Nelson Martins Diniz, Helen de Freitas Santos, Edson Zangiacomi Martinez. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). Journal of Integrative Medicine, 2022, 20(3): 221-229.
[4] Xin Wang, Wen-juan Song, Yi Ruan, Bing-chu Li, Can Lü, Nian Huang, Fan-fu Fang, Wei Gu. Core muscle functional strength training for reducing the risk of low-back pain in military recruits: An open-label randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 145-152.
[5] Shu-yi Chen, Qun-wei Chen, Liu-mei Shou, Hong Pan, Shan-ming Ruan, Zhe-hao Liang, Qi-jin Shu. Stevens-Johnson syndrome/toxic epidermal necrolysis successfully treated with Chinese herbal medicine Pi-Yan-Ning: A case report. Journal of Integrative Medicine, 2021, 19(6): 555-560.
[6] Xin Yin, Shu-bin Cai, Lan-ting Tao, Lu-ming Chen, Zhong-de Zhang, Su-hong Xiao, Arthur Yin Fan, Xu Zou. Recovery of a patient with severe COVID-19 by acupuncture and Chinese herbal medicine adjuvant to standard care. Journal of Integrative Medicine, 2021, 19(5): 460-466.
[7] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[8] Si-chun Gu, Jie Zhou, Qing Ye, Can-xing Yuan. Pingchan granule for depressive symptoms in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2021, 19(2): 120-128.
[9] Jie Wu, Shu-wei Duan, Hong-tao Yang, Yue-yi Deng, Wei Li, Ya-ni He, Zhao-hui Ni, Yong-li Zhan, Shan Lin, Zhi-yong Guo, Jun Zhu, Jing-ai Fang, Xu-sheng Liu, Li-hua Wang, Rong Wang, Nian-song Wang, Xiao-hong Cheng, Li-qun He, Ping Luo, Shi-ren Sun s, Ji-feng Sun, Ai-ping Yin, Geng-ru Jiang, Hong-yu Chen, Wen-hu Liu, Hong-li Lin, Meng Liang, Lu Ma, Ming Chen, Li-qun Song, Jian Chen, Qing Zhu, Chang-ying Xing, Yun Li, Ji-ning Gao, Rong-shan Li, Ying Li, Hao Zhang, Ying Lu, Qiao-ling Zhou, Jun-zhou Fu, Qiang He, Guang-yan Cai, Xiang-mei Chen. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. Journal of Integrative Medicine, 2021, 19(2): 111-119.
[10] Xian Wang, Xuan Yin, Xiu-tian Guo, Yan Wang, Wen-qi Jin, Ai-jun Mao, Lixing Lao, Zhang-jin Zhang, Jie Zhang, Shi-fen Xu. Effects of the pestle needle therapy, a type of acupoint stimulation, on post-hemorrhoidectomy pain: A randomized controlled trial. Journal of Integrative Medicine, 2020, 18(6): 492-498.
[11] Qing-lan Wang, Yan-yan Tao, Hong-dong Xie, Cheng-hai Liu, Ping Liu. Fuzheng Huayu recipe, a traditional Chinese compound herbal medicine, attenuates renal interstitial fibrosis via targeting the miR-21/PTEN/AKT axis. Journal of Integrative Medicine, 2020, 18(6): 505-513.
[12] Ming-sheng Lyu, De-ying Li, Shao-zhong Zhou, Cheng-jun Ban, Jun Yan. Adult-onset Still's disease successfully treated with Chinese herbal medicine: A case report with 15-month follow-up. Journal of Integrative Medicine, 2020, 18(6): 530-534.
[13] Arthur Yin Fan, Sherman Gu, Sarah Faggert Alemi, Research Group for Evidence-based Chinese Medicine. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(5): 385-394.
[14] Bin Lan, Jin-wen Ge, Shao-wu Cheng, Xi-long Zheng, Jun Liao, Chao He, Zheng-qing Rao, Guo-zuo Wang. Extract of Naotaifang, a compound Chinese herbal medicine, protects neuron ferroptosis induced by acute cerebral ischemia in rats. Journal of Integrative Medicine, 2020, 18(4): 344-350.
[15] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228